Trading Report: The ICU Medical Inc. (ICUI) Position Lowered by Prudential Financial Inc.

The ICU Medical Inc. (ICUI) Position Lowered by Prudential Financial Inc.

Prudential Financial Inc. lowered its position in shares of ICU Medical Inc. (NASDAQ:ICUI) by 28.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 65,597 shares of the company’s stock after selling 25,590 shares during the period. Prudential Financial Inc. owned about 0.41% of ICU Medical worth $7,396,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of Montreal Can purchased a new position in ICU Medical during the second quarter worth approximately $133,000. Teacher Retirement System of Texas raised its position in ICU Medical by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 2,003 shares of the company’s stock worth $226,000 after buying an additional 243 shares during the period. Diversified Trust Co purchased a new position in ICU Medical during the second quarter worth approximately $237,000. M&T Bank Corp raised its position in ICU Medical by 3.3% in the first quarter. M&T Bank Corp now owns 2,117 shares of the company’s stock worth $220,000 after buying an additional 67 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new position in ICU Medical during the second quarter worth approximately $240,000. Hedge funds and other institutional investors own 89.50% of the company’s stock.

ICU Medical Inc. (NASDAQ:ICUI) opened at 149.65 on Friday. The company has a 50-day moving average of $126.14 and a 200 day moving average of $112.44. ICU Medical Inc. has a 12 month low of $85.56 and a 12 month high of $150.37. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of 44.57 and a beta of 0.37.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Monday, August 8th. The company reported $1.15 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.10. The company had revenue of $96.70 million for the quarter, compared to the consensus estimate of $89.66 million. ICU Medical had a net margin of 14.94% and a return on equity of 10.33%. The firm’s revenue for the quarter was up 15.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.97 earnings per share. On average, equities research analysts anticipate that ICU Medical Inc. will post $4.54 earnings per share for the current fiscal year.

A number of research firms have recently commented on ICUI. Piper Jaffray Cos. restated a “neutral” rating and set a $119.00 price target (up from $115.00) on shares of ICU Medical in a research report on Thursday, August 11th. Zacks Investment Research upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $140.00 price target for the company in a research report on Friday, August 12th.

In other ICU Medical news, CFO Scott E. Lamb sold 1,474 shares of the stock in a transaction that occurred on Tuesday, September 13th. The shares were sold at an average price of $121.61, for a total value of $179,253.14. Following the transaction, the chief financial officer now directly owns 4,705 shares in the company, valued at $572,175.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard Md Sherman sold 1,500 shares of the stock in a transaction that occurred on Thursday, October 6th. The stock was sold at an average price of $140.60, for a total transaction of $210,900.00. Following the completion of the transaction, the director now owns 70,699 shares in the company, valued at $9,940,279.40. The disclosure for this sale can be found here. 15.90% of the stock is currently owned by company insiders.

ICU Medical Company Profile

ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Related posts

Leave a Comment